News

Video

Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS

Related Videos
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Joseph Franses, MD, PhD
Shipra Gandhi, MD
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
Related Content
Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

D. Ross Camidge, MD, PhD; Kristie L. Kahl, MS, vice president, Content, MJH Life Sciences
July 22nd 2024

Camidge and Kahl Reflect on the Impact of Oncology Journalism

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Justin M. Watts, MD
July 22nd 2024

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

Yucai Wang, MD, PhD, Mayo Clinic
July 22nd 2024

Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Response in Richter Transformation of CLL/SLL